DS
ADMS

Dudley & Shanley’s Adamas Pharmaceuticals ADMS Stock Holding History

Dudley & Shanley’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-67,400
Closed -$345K – 26
2019
Q3 		$345K Hold
67,400
– – 0.09% 23
2019
Q2 		$418K Hold
67,400
– – 0.1% 25
2019
Q1 		$479K Hold
67,400
– – 0.12% 27
2018
Q4 		$576K Buy
67,400
+18,000
+36% +$234K 0.14% 30
2018
Q3 		$989K Buy
49,400
+28,400
+135% +$667K 0.19% 33
2018
Q2 		$542K Sell
21,000
-10,000
-32% -$277K 0.11% 36
2018
Q1 		$741K Buy
+31,000
New +$977K 0.14% 34

Other funds holding ADMS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Dudley & Shanley's ADMS Position: Q4 2019 in Review

Dudley & Shanley sold out of Adamas Pharmaceuticals (ADMS) in Q4 2019, closing a stake of 67,400 shares — an estimated $345K sold.

Dudley & Shanley first reported a position in ADMS in Q1 2018 and held it in 7 quarters. The position peaked at $989K in Q3 2018. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

  • Dudley & Shanley reported no remaining Adamas Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Dudley & Shanley sold 67,400 Adamas Pharmaceuticals shares in Q4 2019, an estimated $345K.
  • Dudley & Shanley first reported a position in Adamas Pharmaceuticals in Q1 2018 and held it in 7 quarters.
  • Dudley & Shanley's Adamas Pharmaceuticals position peaked at $989K in Q3 2018.
  • 79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on Dudley & Shanley's 13F filing for Q4 2019, filed 17 Jan 2020.